Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV9201 in Stage IIIB/IV NSCLC
NCT00923312Phase 2Completed
- Sponsor
- CureVac
- Start
- May 2009
- Primary completion
- Feb 2012
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of CV9201 in non-small cell lung cancer (NSCLC), sponsored by CureVac. Started May 2009; status: completed.
02
Drugs
CV9201
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00923312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923312.